Chem. J. Chinese Universities ›› 2015, Vol. 36 ›› Issue (10): 1961.doi: 10.7503/cjcu20150303

• Physical Chemistry • Previous Articles     Next Articles

Electrocatalytic Performance of Highly Loaded PtNi Intermetallic Nanoparticles for Oxygen Reduction

HUANG Qinghong1,2, ZOU Liangliang2, ZHOU Yi2, ZOU Zhiqing2, ZHANG Xiaogang1,*(), YANG Hui2,*()   

  1. 1.College of Material Science and Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
    2. Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201210, China
  • Received:2015-04-16 Online:2015-10-10 Published:2015-09-18
  • Contact: ZHANG Xiaogang,YANG Hui E-mail:azhangxg@163.com;yangh@sari.ac.cn
  • Supported by:
    † Supported by the National Key Basic Research Program of China(No.2012CB932800) and the National Natural Science Foundation of China(No.21073219)

Abstract:

PtNi/C disordered alloy nanoparticles, synthesized in ethylene glycol solution, were annealed and converted into ordered PtNi/C intermetallic nanoparticles. Such an ordered intermetallic PtNi/C catalyst showed enhanced specific activity and mass activity, which were about 2.3 and 1.66 times those of Pt/C for the oxygen reduction reaction(ORR), in comparison with the Pt/C catalyst. After accelerated stress tests(ASTs), the ORR mass activity of the Pt/C and PtNi/C intermetallic nanoparticles decreased to 88.92% and 36.95% of the initial values, respectively; and the mass activity of PtNi/C intermetallic nanoparticles after ASTs was equivalent to the initial one of the Pt/C catalyst. The enhanced ORR activity and durability of the PtNi/C intermetallic nanoparticles could be attributed to the ordered atomic configuration and the increased content of zero valence metal on the surface of nanoparticles. Moreover, the ordered PtNi/C intermetallic nanoparticles exhibited higher methanol tolerance during the ORR than the Pt/C catalyst.

Key words: Oxygen reduction, PtNi intermetallic nanoparticles, Electrocatalyst, High durability

CLC Number: 

TrendMD: